202 related articles for article (PubMed ID: 26138378)
1. Economic Burden of Undiagnosed Nonvalvular Atrial Fibrillation in the United States.
Turakhia MP; Shafrin J; Bognar K; Goldman DP; Mendys PM; Abdulsattar Y; Wiederkehr D; Trocio J
Am J Cardiol; 2015 Sep; 116(5):733-9. PubMed ID: 26138378
[TBL] [Abstract][Full Text] [Related]
2. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States.
Kim MH; Johnston SS; Chu BC; Dalal MR; Schulman KL
Circ Cardiovasc Qual Outcomes; 2011 May; 4(3):313-20. PubMed ID: 21540439
[TBL] [Abstract][Full Text] [Related]
3. Incremental cost burden to US healthcare payers of atrial fibrillation/atrial flutter patients with additional risk factors.
Amin AN; Jhaveri M; Lin J
Adv Ther; 2011 Oct; 28(10):907-26. PubMed ID: 21971681
[TBL] [Abstract][Full Text] [Related]
4. Cost of atrial fibrillation in United States managed care organizations.
Kim MH; Lin J; Hussein M; Kreilick C; Battleman D
Adv Ther; 2009 Sep; 26(9):847-57. PubMed ID: 19768638
[TBL] [Abstract][Full Text] [Related]
5. Indirect and direct costs of acute coronary syndromes with comorbid atrial fibrillation, heart failure, or both.
Ghushchyan V; Nair KV; Page RL
Vasc Health Risk Manag; 2015; 11():25-34. PubMed ID: 25565859
[TBL] [Abstract][Full Text] [Related]
6. Estimated prevalence of undiagnosed atrial fibrillation in the United States.
Turakhia MP; Shafrin J; Bognar K; Trocio J; Abdulsattar Y; Wiederkehr D; Goldman DP
PLoS One; 2018; 13(4):e0195088. PubMed ID: 29649277
[TBL] [Abstract][Full Text] [Related]
7. Retrospective study of total healthcare costs associated with chronic nonvalvular atrial fibrillation and the occurrence of a first transient ischemic attack, stroke or major bleed.
Boccuzzi SJ; Martin J; Stephenson J; Kreilick C; Fernandes J; Beaulieu J; Hauch O; Kim J
Curr Med Res Opin; 2009 Dec; 25(12):2853-64. PubMed ID: 19916729
[TBL] [Abstract][Full Text] [Related]
8. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States.
Coyne KS; Paramore C; Grandy S; Mercader M; Reynolds M; Zimetbaum P
Value Health; 2006; 9(5):348-56. PubMed ID: 16961553
[TBL] [Abstract][Full Text] [Related]
9. The burden of atrial fibrillation on the hospital sector in Canada.
O'Reilly DJ; Hopkins RB; Healey JS; Dorian P; Sauriol L; Tarride JE; Burke N; Goeree RA
Can J Cardiol; 2013 Feb; 29(2):229-35. PubMed ID: 22652091
[TBL] [Abstract][Full Text] [Related]
10. Economic burden of non-cystic fibrosis bronchiectasis in the first year after diagnosis from a US health plan perspective.
Joish VN; Spilsbury-Cantalupo M; Operschall E; Luong B; Boklage S
Appl Health Econ Health Policy; 2013 Jun; 11(3):299-304. PubMed ID: 23580074
[TBL] [Abstract][Full Text] [Related]
11. Bleeding as an outcome among patients with nonvalvular atrial fibrillation in a large managed care population.
Deitelzweig SB; Pinsky B; Buysman E; Lacey M; Makenbaeva D; Wiederkehr D; Graham J
Clin Ther; 2013 Oct; 35(10):1536-45.e1. PubMed ID: 24075151
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Freeman JV; Zhu RP; Owens DK; Garber AM; Hutton DW; Go AS; Wang PJ; Turakhia MP
Ann Intern Med; 2011 Jan; 154(1):1-11. PubMed ID: 21041570
[TBL] [Abstract][Full Text] [Related]
13. Hospital readmissions in US atrial fibrillation patients: occurrence and costs.
Amin AN; Jhaveri M; Lin J
Am J Ther; 2013; 20(2):143-50. PubMed ID: 23183097
[TBL] [Abstract][Full Text] [Related]
14. Increasing prevalence of atrial fibrillation and flutter in the United States.
Naccarelli GV; Varker H; Lin J; Schulman KL
Am J Cardiol; 2009 Dec; 104(11):1534-9. PubMed ID: 19932788
[TBL] [Abstract][Full Text] [Related]
15. Incidence and economic burden of suspected adverse events and adverse event monitoring during AF therapy.
Kim MH; Lin J; Hussein M; Battleman D
Curr Med Res Opin; 2009 Dec; 25(12):3037-47. PubMed ID: 19852699
[TBL] [Abstract][Full Text] [Related]
16. Contemporary prevalence estimates of undiagnosed and diagnosed atrial fibrillation in the United States.
Turakhia MP; Guo JD; Keshishian A; Delinger R; Sun X; Ferri M; Russ C; Cato M; Yuce H; Hlavacek P
Clin Cardiol; 2023 May; 46(5):484-493. PubMed ID: 36855960
[TBL] [Abstract][Full Text] [Related]
17. Direct treatment cost of atrial fibrillation in the elderly American population: a Medicare perspective.
Lee WC; Lamas GA; Balu S; Spalding J; Wang Q; Pashos CL
J Med Econ; 2008; 11(2):281-98. PubMed ID: 19450086
[TBL] [Abstract][Full Text] [Related]
18. Estimated medical cost reductions associated with apixaban in real-world patients with non-valvular atrial fibrillation.
Amin A; Stokes M; Wu N; Gatt E; Makenbaeva D; Wiederkehr D; Boulanger L
J Med Econ; 2013 Oct; 16(10):1193-202. PubMed ID: 23883416
[TBL] [Abstract][Full Text] [Related]
19. Acute hospital, community, and indirect costs of stroke associated with atrial fibrillation: population-based study.
Hannon N; Daly L; Murphy S; Smith S; Hayden D; Ní Chróinín D; Callaly E; Horgan G; Sheehan O; Honari B; Duggan J; Kyne L; Dolan E; Williams D; Wiley M; Kelly PJ
Stroke; 2014 Dec; 45(12):3670-4. PubMed ID: 25358697
[TBL] [Abstract][Full Text] [Related]
20. [Atrial fibrillation in Germany: A prospective cost of illness study].
Spyra A; Daniel D; Thate-Waschke IM; Berghaus S; Willich S; Zeymer U; Rychlik R
Dtsch Med Wochenschr; 2015 Jul; 140(14):e142-8. PubMed ID: 26182263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
